The highly popular weight loss drug Semaglutide , developed by Novo Nordisk, was launched in December 2017
The FDA requires each drug form to go through its own approval processoral tirzepatide has yet to do so
2 The common adverse reactions reported with Wegovy HD were nausea, vomiting, dysesthesia, constipation, abdominal pain, fatigue, headache, dizziness, hair loss and flatulence
This is not surprising given that the diets effect on the lipid profiles of patients without FH is still controversial
What To Expect At Each Stage During early weeks, common experiences include: Mild nausea Reduced appetite Feeling full more quickly Occasional bloating As you move through the semaglutide weight loss dosage chart, appetite suppression generally becomes more consistent
However, there are more severe side effects of Semaglutide/GLP-1 and Liraglutide that, while rare, should be known